Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Income: 2016-2025

Historic Net Income for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $390.9 million.

  • Tg Therapeutics' Net Income rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Net Income is $390.9 million, which was up 1,286.84% from $28.2 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Net Income peaked at $390.9 million during Q3 2025, and registered a low of -$94.0 million during Q4 2021.
  • In the last 3 years, Tg Therapeutics' Net Income had a median value of $5.1 million in 2025 and averaged $41.8 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 96.60% in 2024, then surged by 10,006.23% in 2025.
  • Tg Therapeutics' Net Income (Quarterly) stood at -$94.0 million in 2021, then grew by 14.49% to -$80.4 million in 2022, then soared by 82.07% to -$14.4 million in 2023, then surged by 261.92% to $23.3 million in 2024, then soared by 10,006.23% to $390.9 million in 2025.
  • Its Net Income was $390.9 million in Q3 2025, compared to $28.2 million in Q2 2025 and $5.1 million in Q1 2025.